Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 27, Issue 4, Pages 863-869Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1185/03007995.2011.554532
Keywords
Saxagliptin; Type 2 diabetes; Elderly; Clinical trials
Funding
- AstraZeneca
- Bristol-Myers Squibb
- Novo Nordisk
- Merck-Serono
- Servier
- Roche
- Novartis
- Eli Lilly
- AZ/BMS
- Boehringer-Ingelheim
- sanofi-aventis
- MannKind
- Takeda
- Daiichi Sankyo
- Forest
- Johnson Johnson
- Amylin
- Boehringer Ingelheim
- Merck
- MSD
Ask authors/readers for more resources
To assess the safety and efficacy of saxagliptin (5 mg once-daily) in older patients (epsilon a parts per thousand yen65 years of age) with inadequately controlled type 2 diabetes. In this retrospective subgroup analysis, data from five randomized, double-blind, placebo-controlled, multicenter, 24-week, phase 3 trials were included. The primary studies evaluated saxagliptin 5 mg once-daily (monotherapy or add-on) in patients aged 18--77 years with HbA(1c) epsilon a parts per thousand yen7.0%% (four studies) or epsilon a parts per thousand yen7.5%% (add-on to glyburide study) versus placebo. The primary efficacy endpoint of each study included in this pooled analysis was HbA(1c) change from baseline to week 24. In the five-study pooled population, 279 (16.6%%) patients were at least 65 years old; 142 received saxagliptin 5 mg once-daily and 137 received placebo. Treatment groups were well-balanced for baseline characteristics within each study. In older patients, the HbA(1c) adjusted mean change from a baseline of 8.1%% was --0.73 +/-+/- 0.16%% (mean +/-+/- SEM) with saxagliptin compared with --0.17 +/-+/- 0.14%% for placebo from a baseline of 8.0%%. Adverse event rates were similar with saxagliptin 5 mg once-daily compared with placebo in older patients. The pooled subgroup analysis of saxagliptin 5 mg once-daily monotherapy and add-on therapy trials demonstrated clinically relevant and significant efficacy for reducing HbA(1c) in older (epsilon a parts per thousand yen65 years) patients. Saxagliptin was well-tolerated in older patients with a low incidence of hypoglycemia and no weight gain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available